Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4440875 | 1.00 | NPC1 (0.47) | NPC1RAB9AKMT2ACARM1PRMT6 | |
| SCHEMBL4448649 | 1.00 | NPC1 (0.47) | NPC1RAB9AKMT2ACARM1PRMT6 | |
| Oxalic Acid SCHEMBL4436798 | 0.95 | TSHR (0.46) | NPC1RAB9AKMT2ATSHRCACNA2D1 | |
| SCHEMBL27632851 | 0.87 | NPC1 (0.49) | NPC1RAB9AKMT2ASLC5A2SIGMAR1 | |
| SCHEMBL10979368 | 0.85 | TSHR (0.52) | NPC1RAB9AKMT2ACARM1PRMT6 | |
| SCHEMBL28754037 | 0.85 | TSHR (0.52) | NPC1RAB9AKMT2ACARM1PRMT6 | |
| SCHEMBL15247732 | 0.84 | CARM1 (0.46) | CARM1PRMT6PRMT8TSHRSIGMAR1 | |
| SCHEMBL15247733 | 0.84 | CARM1 (0.46) | CARM1PRMT6PRMT8TSHRSIGMAR1 | |
| SCHEMBL15247731 | 0.84 | CARM1 (0.46) | CARM1PRMT6PRMT8TSHRSIGMAR1 | |
| SCHEMBL15234415 | 0.82 | TSHR (0.50) | CARM1PRMT6PRMT8TSHRCACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125772-B1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT (HU) | 2013-09-11 | — | — | EP | claimed |
| EP-2125772-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | Richter Gedeon NYRT (HU) | 2009-12-02 | — | — | EP | claimed |
| WO-2008078124-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT. (HU) | 2008-07-03 | — | — | WO | claimed |
| EP-1765766-B1 | METHOD FOR PRODUCING ENANTIOMERS 3-HYDROXY-3-PHENYL-PROPYLAMINES | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-09-25 | — | — | EP | disclosed |
| EP-2125772-B1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT (HU) | 2013-09-11 | — | — | EP | disclosed |
| EP-2125772-B1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT (HU) | 2013-09-11 | — | — | EP | disclosed |
| EP-2125772-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | Richter Gedeon NYRT (HU) | 2009-12-02 | — | — | EP | disclosed |
| US-7550605-B2 | Process for preparation of an anitdepressant compound | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2009-06-23 | — | — | US | disclosed |
| US-7550605-B2 | Process for preparation of an anitdepressant compound | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2009-06-23 | — | — | US | disclosed |
| WO-2008078124-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT. (HU) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008078124-A1 | A PROCESS FOR THE PREPARATION OF DULOXETIN AND NEW KEY INTERMEDIATES FOR USE THEREIN | RICHTER GEDEON NYRT. (HU) | 2008-07-03 | — | — | WO | disclosed |
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-01-12 | — | — | US | disclosed |
| US-20050272930-A1 | Process for the prepation of 3-hydroxy-(2-thienyl)propanamines | HEMS WILLIAM | 2005-12-08 | — | — | US | disclosed |
| WO-2005085192-A1 | METHOD FOR PRODUCING N-ALKYL-N-METHYL-3-HYDROXY-3-(2-THIENYL)-PROPYLAMINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050197503-A1 | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| US-20050171360-A1 | Preparation of n-methyl-3-hydroxy- 3-(2-thienyl)propylamine via novel thiophene derivatives containing carbamate groups as intermediates | DEGUSSA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| EP-1506965-A1 | PROPANOLAMINE DERIVATIVES, PROCESS FOR PREPARATION OF 3-N-METHYLAMINO-1-(2-THIENYL)-1-PROPANOLS AND PROCESS FOR PREPARATION OF PROPANOLAMINE DERIVATIVES | Mitsubishi Rayon Co., Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1476439-A1 | PREPARATION OF N-METHYL-3-HYDROXY- 3-(2-THIENYL)PROPYLAMINE VIA NOVEL THIOPHENE DERIVATIVES CONTAINING CARBAMATE GROUPS AS INTERMEDIATES | Degussa AG (DE) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003070720-A1 | PREPARATION OF N-METHYL-3-HYDROXY- 3-(2-THIENYL)PROPYLAMINE VIA NOVEL THIOPHENE DERIVATIVES CONTAINING CARBAMATE GROUPS AS INTERMEDIATES | DEGUSSA AG (DE) | 2003-08-28 | — | — | WO | disclosed |
| EP-0457559-A2 | Chiral synthesis of 1-aryl-3-aminopropan-1-ols | ELI LILLY AND COMPANY (US) | 1991-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009533-A1 | Process for manufacturing of enantiomerically pure 3-hydroxy-3-phenyl-propylamin | HPD, HNMT, PNMT | NPC1 3366/4885RAB9A 3446/4885KMT2A 586/4885 |
| US-20050272930-A1 | Process for the prepation of 3-hydroxy-(2-thienyl)propanamines | PNMT, HPD, HRH3 | NPC1 4437/4885RAB9A 2150/4885KMT2A 1054/4885 |
| US-20050197503-A1 | Process for the preparation of N-alkyl-N-methyl-3-hydroxy-3-(2-thienyl)-propylamines | HNMT, PNMT, HRH4 | NPC1 3703/4885RAB9A 3317/4885KMT2A 148/4885 |
| US-20050171360-A1 | Preparation of n-methyl-3-hydroxy- 3-(2-thienyl)propylamine via novel thiophene derivatives containing carbamate groups as intermediates | HTR3C, PNMT, HTR2C | NPC1 3090/4885RAB9A 3873/4885KMT2A 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.